PBS-1086, A rel inhibitor of NF-κB, ameliorates collagen-induced arthritis in mice

D. Impellizzeri, E. Mazzon, R. Di Paola, M. Galuppo, P. Bramanti, J. Zhang, K. Bobb, D. Monie, J. Meshulam, D. R. Sliskovic, Salvatore Cuzzocrea

Research output: Contribution to journalArticle

Abstract

The family of nuclear factor-kappaB (NF-κB) transcription factors is intimately involved in the regulation of expression of numerous genes in the setting of the inflammatory response. Inflammation, cartilage degradation, cell proliferation, angiogenesis and pannus formation are hallmarks of the pathogenesis of both collagen-induced arthritis (CIA) in rodents and rheumatoid arthritis (RA) in humans. The aim of this study is to investigate the effect of PBS-1086, a Rel inhibitor of NF-κB, on the modulation of the inflammatory response in mice subjected to CIA in comparison to the effect of etanercept. CIA was induced in mice by an intradermal injection of bovine type II collagen (CII) emulsion and complete Freund's adjuvant (CFA) at the base of the tail. On day 21, a second injection of CII in CFA was administered. Mice developed erosive hind paw arthritis when immunised with CII in CFA. Macroscopic clinical evidence of CIA first appeared as peri-articular erythema and oedema in the hind paws. The incidence of CIA was 100% by day 28 in the CII challenged mice and the severity of CIA progressed over a 35-day period with a resorption of bone. The histopathology of CIA included erosion of the cartilage at the joint. Treatment with PBS-1086 starting at the onset of arthritis (day 21) ameliorated the clinical signs at days 21-35 and improved histological status in the joint and paw. In addition, it also reduced the neutrophil infiltration which is a key mediator of RA. In this study, we demonstrate that PBS-1086 exerts an anti-inflammatory effect during chronic inflammation and ameliorates the tissue damage associated with CIA. The anti-inflammatory activities of PBS-1086 are comparable to those of etanercept treatment.

Original languageEnglish (US)
Pages (from-to)51-59
Number of pages9
JournalEuropean Journal of Inflammation
Volume10
Issue number1
StatePublished - Jan 2012
Externally publishedYes

Fingerprint

Experimental Arthritis
Freund's Adjuvant
Joints
Arthritis
Cartilage
Rheumatoid Arthritis
Anti-Inflammatory Agents
Inflammation
Intradermal Injections
Collagen Type II
Neutrophil Infiltration
PBS-1086
Gene Expression Regulation
Erythema
Bone Resorption
Emulsions
Nuclear Family
Tail
Rodentia
Edema

Keywords

  • Arthritis
  • Cytokines
  • Inflammation
  • Myeloperoxidase
  • NF-κB

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Impellizzeri, D., Mazzon, E., Di Paola, R., Galuppo, M., Bramanti, P., Zhang, J., ... Cuzzocrea, S. (2012). PBS-1086, A rel inhibitor of NF-κB, ameliorates collagen-induced arthritis in mice. European Journal of Inflammation, 10(1), 51-59.

PBS-1086, A rel inhibitor of NF-κB, ameliorates collagen-induced arthritis in mice. / Impellizzeri, D.; Mazzon, E.; Di Paola, R.; Galuppo, M.; Bramanti, P.; Zhang, J.; Bobb, K.; Monie, D.; Meshulam, J.; Sliskovic, D. R.; Cuzzocrea, Salvatore.

In: European Journal of Inflammation, Vol. 10, No. 1, 01.2012, p. 51-59.

Research output: Contribution to journalArticle

Impellizzeri, D, Mazzon, E, Di Paola, R, Galuppo, M, Bramanti, P, Zhang, J, Bobb, K, Monie, D, Meshulam, J, Sliskovic, DR & Cuzzocrea, S 2012, 'PBS-1086, A rel inhibitor of NF-κB, ameliorates collagen-induced arthritis in mice', European Journal of Inflammation, vol. 10, no. 1, pp. 51-59.
Impellizzeri D, Mazzon E, Di Paola R, Galuppo M, Bramanti P, Zhang J et al. PBS-1086, A rel inhibitor of NF-κB, ameliorates collagen-induced arthritis in mice. European Journal of Inflammation. 2012 Jan;10(1):51-59.
Impellizzeri, D. ; Mazzon, E. ; Di Paola, R. ; Galuppo, M. ; Bramanti, P. ; Zhang, J. ; Bobb, K. ; Monie, D. ; Meshulam, J. ; Sliskovic, D. R. ; Cuzzocrea, Salvatore. / PBS-1086, A rel inhibitor of NF-κB, ameliorates collagen-induced arthritis in mice. In: European Journal of Inflammation. 2012 ; Vol. 10, No. 1. pp. 51-59.
@article{925f1f49a502462eba556dfb3bc9b9c6,
title = "PBS-1086, A rel inhibitor of NF-κB, ameliorates collagen-induced arthritis in mice",
abstract = "The family of nuclear factor-kappaB (NF-κB) transcription factors is intimately involved in the regulation of expression of numerous genes in the setting of the inflammatory response. Inflammation, cartilage degradation, cell proliferation, angiogenesis and pannus formation are hallmarks of the pathogenesis of both collagen-induced arthritis (CIA) in rodents and rheumatoid arthritis (RA) in humans. The aim of this study is to investigate the effect of PBS-1086, a Rel inhibitor of NF-κB, on the modulation of the inflammatory response in mice subjected to CIA in comparison to the effect of etanercept. CIA was induced in mice by an intradermal injection of bovine type II collagen (CII) emulsion and complete Freund's adjuvant (CFA) at the base of the tail. On day 21, a second injection of CII in CFA was administered. Mice developed erosive hind paw arthritis when immunised with CII in CFA. Macroscopic clinical evidence of CIA first appeared as peri-articular erythema and oedema in the hind paws. The incidence of CIA was 100{\%} by day 28 in the CII challenged mice and the severity of CIA progressed over a 35-day period with a resorption of bone. The histopathology of CIA included erosion of the cartilage at the joint. Treatment with PBS-1086 starting at the onset of arthritis (day 21) ameliorated the clinical signs at days 21-35 and improved histological status in the joint and paw. In addition, it also reduced the neutrophil infiltration which is a key mediator of RA. In this study, we demonstrate that PBS-1086 exerts an anti-inflammatory effect during chronic inflammation and ameliorates the tissue damage associated with CIA. The anti-inflammatory activities of PBS-1086 are comparable to those of etanercept treatment.",
keywords = "Arthritis, Cytokines, Inflammation, Myeloperoxidase, NF-κB",
author = "D. Impellizzeri and E. Mazzon and {Di Paola}, R. and M. Galuppo and P. Bramanti and J. Zhang and K. Bobb and D. Monie and J. Meshulam and Sliskovic, {D. R.} and Salvatore Cuzzocrea",
year = "2012",
month = "1",
language = "English (US)",
volume = "10",
pages = "51--59",
journal = "European Journal of Inflammation",
issn = "1721-727X",
publisher = "Biolife",
number = "1",

}

TY - JOUR

T1 - PBS-1086, A rel inhibitor of NF-κB, ameliorates collagen-induced arthritis in mice

AU - Impellizzeri, D.

AU - Mazzon, E.

AU - Di Paola, R.

AU - Galuppo, M.

AU - Bramanti, P.

AU - Zhang, J.

AU - Bobb, K.

AU - Monie, D.

AU - Meshulam, J.

AU - Sliskovic, D. R.

AU - Cuzzocrea, Salvatore

PY - 2012/1

Y1 - 2012/1

N2 - The family of nuclear factor-kappaB (NF-κB) transcription factors is intimately involved in the regulation of expression of numerous genes in the setting of the inflammatory response. Inflammation, cartilage degradation, cell proliferation, angiogenesis and pannus formation are hallmarks of the pathogenesis of both collagen-induced arthritis (CIA) in rodents and rheumatoid arthritis (RA) in humans. The aim of this study is to investigate the effect of PBS-1086, a Rel inhibitor of NF-κB, on the modulation of the inflammatory response in mice subjected to CIA in comparison to the effect of etanercept. CIA was induced in mice by an intradermal injection of bovine type II collagen (CII) emulsion and complete Freund's adjuvant (CFA) at the base of the tail. On day 21, a second injection of CII in CFA was administered. Mice developed erosive hind paw arthritis when immunised with CII in CFA. Macroscopic clinical evidence of CIA first appeared as peri-articular erythema and oedema in the hind paws. The incidence of CIA was 100% by day 28 in the CII challenged mice and the severity of CIA progressed over a 35-day period with a resorption of bone. The histopathology of CIA included erosion of the cartilage at the joint. Treatment with PBS-1086 starting at the onset of arthritis (day 21) ameliorated the clinical signs at days 21-35 and improved histological status in the joint and paw. In addition, it also reduced the neutrophil infiltration which is a key mediator of RA. In this study, we demonstrate that PBS-1086 exerts an anti-inflammatory effect during chronic inflammation and ameliorates the tissue damage associated with CIA. The anti-inflammatory activities of PBS-1086 are comparable to those of etanercept treatment.

AB - The family of nuclear factor-kappaB (NF-κB) transcription factors is intimately involved in the regulation of expression of numerous genes in the setting of the inflammatory response. Inflammation, cartilage degradation, cell proliferation, angiogenesis and pannus formation are hallmarks of the pathogenesis of both collagen-induced arthritis (CIA) in rodents and rheumatoid arthritis (RA) in humans. The aim of this study is to investigate the effect of PBS-1086, a Rel inhibitor of NF-κB, on the modulation of the inflammatory response in mice subjected to CIA in comparison to the effect of etanercept. CIA was induced in mice by an intradermal injection of bovine type II collagen (CII) emulsion and complete Freund's adjuvant (CFA) at the base of the tail. On day 21, a second injection of CII in CFA was administered. Mice developed erosive hind paw arthritis when immunised with CII in CFA. Macroscopic clinical evidence of CIA first appeared as peri-articular erythema and oedema in the hind paws. The incidence of CIA was 100% by day 28 in the CII challenged mice and the severity of CIA progressed over a 35-day period with a resorption of bone. The histopathology of CIA included erosion of the cartilage at the joint. Treatment with PBS-1086 starting at the onset of arthritis (day 21) ameliorated the clinical signs at days 21-35 and improved histological status in the joint and paw. In addition, it also reduced the neutrophil infiltration which is a key mediator of RA. In this study, we demonstrate that PBS-1086 exerts an anti-inflammatory effect during chronic inflammation and ameliorates the tissue damage associated with CIA. The anti-inflammatory activities of PBS-1086 are comparable to those of etanercept treatment.

KW - Arthritis

KW - Cytokines

KW - Inflammation

KW - Myeloperoxidase

KW - NF-κB

UR - http://www.scopus.com/inward/record.url?scp=84861705806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861705806&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84861705806

VL - 10

SP - 51

EP - 59

JO - European Journal of Inflammation

JF - European Journal of Inflammation

SN - 1721-727X

IS - 1

ER -